Srinagar Observer
Tuesday, July 8, 2025
  • Home
  • Top News
  • Kashmir
  • Jammu
  • Business
  • Sports
  • National
  • World
  • Editorial

    The Habitual Shifts

    Assuring Crime Free Society

    Stimulating Young Energy

    An Ethical Denial

    Beating Inflation

    The Timely Exigence

    Extension in Academics

     Aiding Healthcare

    Development in Disguise

    Gender-Free Conviction

  • Edit-Oped
  • ePaper
No Result
View All Result
Srinagar Observer
  • Home
  • Top News
  • Kashmir
  • Jammu
  • Business
  • Sports
  • National
  • World
  • Editorial

    The Habitual Shifts

    Assuring Crime Free Society

    Stimulating Young Energy

    An Ethical Denial

    Beating Inflation

    The Timely Exigence

    Extension in Academics

     Aiding Healthcare

    Development in Disguise

    Gender-Free Conviction

  • Edit-Oped
  • ePaper
No Result
View All Result
Srinagar Observer
No Result
View All Result
Home Business

Sanofi-GSK reports success in virus vaccine, after setback

SO NEWS Desk by SO NEWS Desk
May 17, 2021
in Business, Latest, Uncategorized
A A
0
Share on FacebookShare on TwitterWhatsApp

Paris: Sanofi and GlaxoSmithKline’s potential COVID-19 vaccine triggered strong immune responses in all adult age groups in preliminary trials after an earlier setback, boosting optimism the shot may join the fight against the pandemic this year.

After two doses of the vaccine candidate, participants showed neutralising antibodies in line with those found in people who had recovered from the disease, according to results of the Phase 2 trial released Monday.

RELATED POSTS

GMC Srinagar achieves feat, performs 10 consecutive primary PCIs in 24 hrs

SANJY-2025: LG Sinha visits Nunwan base camp at Pahalgam

The drugmakers said they plan to begin late-stage trials and production in the coming weeks and hope to win regulatory approval for the vaccine before the end of 2021.

Regulators have already authorised a number of COVID-19 vaccines, though experts say more are needed as public health authorities around the world race to vaccinate their residents amid a pandemic that has already killed more than 3.3 million people and caused economic havoc.

The Sanofi-GSK vaccine was an important part of the European Union’s vaccination strategy, and had notably been championed by French President Emmanuel Macron’s government.

But researchers had to reformulate it after early testing produced an inadequate immune response in older people.

The Sanofi-GSK candidate joins about a dozen vaccines now undergoing late-stage trials.

The companies plan to produce up to 1 billion doses annually, and they have signed agreements to supply the US, Canada and developing countries, too. Public health experts say several vaccines will be needed to end the pandemic, because of the challenges in rapidly producing and distributing enough doses to vaccinate billions of people.

We know multiple vaccines will be needed, especially as variants continue to emerge and the need for effective and booster vaccines which can be stored at normal temperatures increases, said Thomas Triomphe, head of Sanofi’s vaccines unit.

The results released Monday were from a Phase 2 trial involving 722 volunteers aged 18 to 95 who were recruited in the US and Honduras.

The vaccine showed even stronger antibody results in people who had already recovered from the virus. Sanofi said that makes it a potentially strong candidate as a booster shot in the future for those who have already been vaccinated with rival products.

The late-stage trial will involve about 37,000 participants from countries around the world, the companies said. They plan to study its efficacy against the virus variant first identified in South Africa, and potentially others as well.

After the initial setback, Sanofi struck agreements to help bottle or produce rival vaccines designed by Pfizer, Moderna and Johnson&Johnson. The progress in the Sanofi-GSK vaccine will not disrupt those production plans, Triomphe said.(AP)

Related

ShareTweetSend
SO NEWS Desk

SO NEWS Desk

Related Posts

GMC Srinagar achieves feat, performs 10 consecutive primary PCIs in 24 hrs

by SO NEWS Desk
July 7, 2025
0

SRINAGAR, JULY 07 - The Cardiology Department of Government Medical College (GMC) Srinagar has achieved a remarkable milestone by successfully...

SANJY-2025: LG Sinha visits Nunwan base camp at Pahalgam

by SO NEWS Desk
July 7, 2025
0

Interacts with Pilgrims, officials, service providers, langar sevadars, sanitation workers; reviews Yatra arrangement SRINAGAR, JULY 07: Lieutenant Governor Shri Manoj...

Oplus_0

We should encourage young people to treat everyone to build a just and humane society: LG Sinha

by SO NEWS Desk
July 7, 2025
0

ANANTNAG, JULY 07: On the auspicious occasion of ‘Harbah Utsav’, the Lieutenant Governor Shri Manoj Sinha paid obeisance at Mata...

Vocal for Local is the pathway to Viksit Bharat: Piyush Goyal

by SO NEWS Desk
July 6, 2025
0

SRINAGAR, JUNE 06 - Union Minister of Commerce and Industry, Shri Piyush Goyal, addressed the Traders’ Conclave – 2025, organised...

Satish Sharma advocates digital empowerment, youth led entrepreneurship at FTII Traders Conclave 2025

by SO NEWS Desk
July 6, 2025
0

Calls for Integration of IT, Consumer Welfare, Skill Development for stronger trade ecosystem SRINAGAR, JULY 6: Minister for Food, Civil...

Next Post
Doctor drawing up Covid-19 vaccine from glass phial bottle and filling syringe injection for vaccination. Close up of hand wearing protective disposable gloves in lab and holding a bottle of vaccination drugs. Hand with blue surgical gloves taking sars-coV-2 vaccine dose from vial with syringe: prevention and immunization concept.

Over 2 Cr COVID-19 vaccine doses available with states: Centre

Israel says Gaza tunnels destroyed in heavy airstrikes

Digital Edition

Srinagar Observer

Srinagar Observer is an English Newspaper based in Jammu and Kashmir

CATEGORY

  • Business
  • Edit-Oped
  • Editorial
  • Jammu
  • Kashmir
  • Latest
  • National
  • Photo Gallery
  • Sports
  • Top News
  • Uncategorized
  • World

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 9,375 other subscribers

Archives

No Result
View All Result
  • Home
  • About Us
  • Contact Us
  • Advertise

© 2024 Srinagar Observer - Designed by GITS.

No Result
View All Result
  • Home
  • Top News
  • Kashmir
  • Jammu
  • Business
  • Sports
  • National
  • World
  • Editorial
  • Edit-Oped
  • ePaper

© 2024 Srinagar Observer - Designed by GITS.